Connect with us

Technology

Leading a Paradigm Shift, Exploring the Next Decade Together — 2026 World Laureates Forum to take place in Shanghai from October 30 to November 1

Published

on

SHANGHAI, Oct. 27, 2026 /PRNewswire/ —  A news report from Yicai Global:

A press conference for the 2026 World Laureates Forum (WLF) was held in Lingang, Shanghai, on October 22. WU Xiaohua, Chairman of the World Laureates Foundation, presented an overview of this year’s forum and its key highlights. Six other speakers then took turns outlining the agendas and highlights of the six parallel forums and answering questions from reporters. The speakers were HU Dawei, Vice President of Shanghai University; XU Xu, Deputy Secretary of the Party Committee of Lingang Laboratory; MENG Guang, Deputy Chair of the University Council at Shanghai Jiao Tong University; YANG Yanqin, Secretary of the Party Committee of Software Engineering Institute at East China Normal University; GENG Zhaohua, Vice Dean of the Xuemin Institute of Advanced Studies at Fudan University; and ZHAO Hongduo, Assistant President of Tongji University. The press conference was chaired by FAN Jianrong, Secretary-General of the World Laureates Foundation.

According to information released at the press conference, the 2026 WLF will take place from October 30 to November 1 at its permanent venue, the Lingang Center in Shanghai, under the theme “New Science Paradigm: Break Through for the Next Decade.” The opening ceremony and main forum will be held on the morning of October 31. WAN Gang, former President of the China Association for Science and Technology, will serve as the forum’s Chinese chair, and Randy W. SCHEKMAN, a recipient of the 2013 Nobel Prize in Physiology or Medicine, will serve as its international chair. The forum is hosted by the China Association for Science and Technology and co-hosted by the Parkland Foundation and the HongShan Charity Foundation. As many as 25 international and domestic scientific organizations, leading universities, and top laboratories will organize or support the event.

This year’s forum will bring together 33 recipients of leading international awards, including the Nobel Prize, Turing Award, Wolf Prize, and Fields Medal, alongside numerous members of the Chinese Academy of Sciences (CAS), the Chinese Academy of Engineering (CAE), and overseas academies, distinguished experts and scholars, outstanding young scientists, and representatives of leading sci-tech enterprises. Focusing on the frontiers of global science and technology, the participants will discuss major issues concerning future sciences, including research paradigms, value chains, international cooperation, talent development, and science and technology governance.

The forum follows a “1+6+4+1” structure: one combined event comprising the opening ceremony, award ceremony, and main forum; six parallel forums; four themed events; and one closing ceremony. These will be complemented by a series of special activities, including science and technology tours and related exchange events. Together, the activities will engage leading scientists, senior researchers, young scientists, young people involved in science and technology innovation, and industrial incubation platforms. The opening ceremony will also feature the presentation of the 2026 WLF Prize in Computer Science or Mathematics and the 2026 WLF Prize in Life Science or Medicine, alongside the 2026 WLF Prize for Young Scientists, newly introduced this year.

Seven Key Highlights

Compared with previous editions, this year’s forum will feature an enhanced program with seven key highlights.

A more distinguished lineup of participants

33 leading scientists have confirmed their attendance, including seven Nobel laureates and three Turing Award laureates. Of these 33 scientists, seven will be attending the forum for the first time. They will be joined by 139 senior scientists and 81 young scientists, forming a distinctly tiered talent structure. Notably, participation by high-level Chinese scholars and members of the Chinese Academy of Sciences and the Chinese Academy of Engineering will increase significantly this year, further strengthening the lineup.

2026 WLF Prize laureates to be officially introduced at the opening ceremony

The 2026 WLF Prize Laureates were officially announced at the Lingang Center on September 10. The laureates, including SHAO Feng, the first Chinese national to win the prize, will receive their awards at the opening ceremony. Leading scientists from China and abroad, including Andrew Chi-Chih YAO, Liqun LUO, Efim ZELMANOV, and Randy W. SCHEKMAN, will attend to announce the awards and present them to the laureates. In addition, this year’s WLF Prize laureates will take part in a series of WLF Prize campus visits, meeting and exchanging ideas with young scholars at leading universities in Shanghai and Hong Kong.

A more prestigious opening ceremony and main forum

As the forum’s flagship event, the opening ceremony and main forum will retain their three customary components: opening addresses, the awards ceremony, and keynote speeches. This year’s opening ceremony will take place at the Summit Grand Ballroom in the Lingang Center and with roughly double the seating of last year’s ceremony.The main forum will be a particular highlight. Omar M. YAGHI, a recipient of the 2025 Nobel Prize in Chemistry; HU Hailan, a female member of Chinese Academy of Sciences; Laurent LAFFORGUE, a 2002 Fields Medalist; and ZENG Yuqun, founder and chairman of CATL, will deliver keynote speeches in that order. This will mark the first time that a leading scientist from industry joins recipients of top scientific awards on stage to discuss the forum’s central themes.

Six parallel forums focusing on the frontiers of science and technology

The six parallel forums will focus on six emerging or frontier fields: future semiconductors, biomedicine, aerospace information, artificial intelligence, future energy, and quantum science. The forums will be organized by Shanghai University, Lingang Laboratory, Shanghai Jiao Tong University, East China Normal University, Fudan University, and Tongji University, respectively, in collaboration with national academic societies and leading companies.

Four engaging themed events

The Young Scientists Forum, themed “The Next Decade: Young Scientists Define Questions, Science Reshapes the Future,” will bring together laureates of the WLF Prize for Young Scientists and young scholars from around the world, giving them the opportunity to engage in dialogue with leading scientists.

The SHE Forum, themed “The Next Decade: Women’s Leadership in Science and a Resilient Future in the Age of AI,” will highlight the contributions and influence of women in science and technology worldwide.

The Future Scientists Forum, designed for children and teenagers and themed “The Next Decade: My Pact with Science,” will offer young participants opportunities to meet leading scientists from China and abroad face to face and inspire them to pursue their scientific dreams.

The World Top-Performing Incubator Conference, themed “The Next Decade: Deep Tech Transfer, The Critical Leap from Lab to Market,” will bring together incubator leaders from around the world to promote the incubation and commercialization of deep-tech research outcomes.

A series of distinctive side events

Science and technology tours along four routes will take participants to major research facilities and leading technology companies in Shanghai, including Tongji University’s intelligent connected vehicle testing and evaluation base, the National Facility for Protein Science in Shanghai, the Shanghai Astronomy Museum, and JCET’s automotive electronics facility. The tours will provide a comprehensive view of the latest achievements in Shanghai’s development as an international center for science and technology innovation.

The WLF HUB will be open to young researchers free of charge. A research poster exhibition featuring work by young scientists will also be held during the forum to showcase their latest findings at the frontiers of science and foster collaboration among industry, universities, and research institutes.

During the forum, a temporary exhibition titled “Liu Hui: The Great Mathematician of Ancient China,” will also be held in Shanghai. Through rare editions of historical texts, art installations, digital films, and interactive experiences, the exhibition will showcase the remarkable achievements of ancient Chinese mathematics and promote exchanges and mutual learning among civilizations.

Major outcomes to be unveiled at the closing ceremony

Next year will mark the 10th anniversary of the WLF. Under the theme “WLF’s 10th Anniversary: A New Beginning,” this year’s closing ceremony will highlight the key outcomes of this year’s forum, launch the global call for nominations for the 2027 WLF Prize, and formally put forward a proposal to establish an international organization. Together, these announcements will set out a blueprint for the forum’s transition from an annual gathering to a permanent platform for international cooperation in science and technology.

Six Parallel Forums

2026 marks the first year of China’s 15th Five-Year Plan period (2026–2030), with proactive planning for future industries becoming a key priority. In collaboration with leading universities in Shanghai, research institutions, and national academic societies, the 2026 WLF will organize six parallel forums covering future semiconductors, biomedicine, aerospace information, artificial intelligence, future energy, and quantum science. Aligned with national strategic deployments and Shanghai’s industrial development priorities, the forums will look ahead to the next decade and address key questions concerning scientific breakthroughs and industrial transformation across these six fields.

The Future Semiconductor Forum is jointly hosted by the Chinese Institute of Electronics and Shanghai University, with support from Fudan University, the Shanghai Institute of Microelectronics Industry at Shanghai University, and the journals Acta Electronica Sinica, Journal of Mechanical Engineering, and Moore and More. Academicians LIU Ming (female), WU Hanming, and Benoît DUBUIS will serve as co-chairs. ZHANG Jianhua (female), Vice President of Shanghai University, will serve as chair of the Organizing Committee. Academicians LIU Sheng and Adrian Mihai IONESCU, along with other experts, will participate in the discussions at the forum. Under the theme “The Next Decade: The Future of Semiconductors and Chips,” the forum will explore how AI can drive innovation and development in the semiconductor industry, assess technological development trajectories over the next decade, and examine models for training innovative talent.

The Lingang Symposium on Brain Diseases, initiated by Lingang Laboratory, is jointly hosted by the laboratory, the Chinese Society for Biomaterials, and the Chinese Society for Cell Biology. Nobel laureate Randy W. SCHEKMAN, WLF Prize laureate YUAN Junying (female), CAS Academician HU Hailan (female), and other distinguished scientists will share their latest findings. Focusing on major cerebral diseases, including Alzheimer’s disease, Parkinson’s disease, and depression, the forum will adopt a “3+1” structure, comprising three disease-focused sessions and one session dedicated to translational medicine, under the theme “The Next Decade: From Neuroscience Discoveries to Translational Medicine Breakthroughs.”

The Aerospace Forum is jointly hosted by the Chinese Society of Astronautics, the International Astronautical Federation (IAF), and Shanghai Jiao Tong University, with support from the Shanghai Institute of Technical Physics and the Innovation Academy for Microsatellites, both under the Chinese Academy of Sciences. Christian FEICHTINGER, Executive Director of the IAF, and CAS Academician HAN Jiecai, President of Harbin Institute of Technology, will serve as co-chairs. Sir Martin SWEETING, Academicians WANG Jianyu and LI Dong, and other experts will participate in the discussions. Under the theme “The Next Decade: Explore Universe, Benefit Humanity,” the forum aims to build an interdisciplinary hub for an increasingly interconnected space sector, linking overarching strategy, frontier technologies, engineering applications, and international cooperation.

The Artificial Intelligence Forum is jointly hosted by East China Normal University, the Chinese Association of Automation, and the China Institute of Communications, with support from Cambricon Technologies and Journal on Communications. CAS Academician HE Jifeng and Turing Award laureate Joseph SIFAKIS will serve as co-chairs. Turing Award laureates Martin HELLMAN and Jack DONGARRA, alongside industry representatives including CHEN Yunji and GAO Quanzhong, will participate in the discussions. Under the theme “The Next Decade: The Evolution and Governance of Artificial Intelligence,” the forum will place equal emphasis on technological innovation and ethical governance. Discussions will focus on cutting-edge technologies such as trustworthy AI, high-performance computing, AI chips, and humanoid robotics, as well as common challenges in global AI governance, aiming to help build a fair and equitable governance framework.

The Future Energy Forum and Watt Annual Meeting are jointly hosted by Fudan University, Watt, the Chinese Society for Electrical Engineering, CATL’s 21C Lab, and other organizations. Under the theme “The Next Decade: Future Energy, Energy Storage, and Computing Power Centers,” the forum will bring together the academic publishing community and industry to help translate research breakthroughs into practical applications. It will focus on new energy technologies, large-scale energy storage, energy use in computing centers, and space-based photovoltaics. Nobel laureate in Physics Konstantin NOVOSELOV, Eni Award laureate Jürgen CARO, and other distinguished experts will present the latest advances in the field.

The Quantum Science Forum is jointly hosted by the Chinese Physical Society, Tongji University, and the University of Science and Technology of China. Academicians YANG Jinlong and PAN Jianwei, together with Sir Andre GEIM, will serve as co-chairs. Under the theme “The Next Decade: Toward Practical Quantum Computing,” the forum will bring together Nobel laureates, academy members from China and abroad, leading young researchers, and founders of quantum technology companies. Through exchanges across disciplines and from diverse perspectives, the forum will explore the key challenges, pathways, and development trends in translating quantum technologies from the laboratory into industrial applications.

Themed Events and Special Activities

This year’s WLF will feature four major themed events: the Young Scientists Forum, the SHE Forum, the Future Scientists Forum, and the World Top-Performing Incubator Conference. They will focus, respectively, on exchanges among young scholars, showcasing the contributions of women in science and technology, inspiring scientific curiosity among children and teenagers, and promoting the incubation and commercialization of scientific and technological research outcomes. Together, these events will foster dialogue across the full spectrum of scientific enlightenment, talent development, and industrial application, helping to drive future innovation.

The forum will further strengthen collaboration between universities and local partners in science, technology, and innovation, providing a strong impetus to Shanghai’s development. Closely aligned with Shanghai’s efforts to build an international center for science and technology innovation, it will arrange four science and technology tour routes to comprehensively showcase the city’s major research infrastructure and its latest achievements in collaboration among industry, universities, and research institutes.

A series of engaging side events will bring the appeal of science beyond the conference venue. The World Laureates HUB will provide an informal space for scientists to exchange ideas freely, allowing researchers from different fields to spark new ideas and explore collaborations across disciplines. A series of campus visits by WLF Prize laureates will bring leading scientists to campuses and the front lines of research. For the first time, the scientists will leave Shanghai and travel to the Guangdong-Hong Kong-Macao Greater Bay Area, where, at The Hong Kong Polytechnic University, they will meet students face to face, sharing their scientific ideas and the spirit of science with the younger generation.

CHEN Xin, vice chair of the Shanghai Association for Science and Technology, attended the press conference, along with senior representatives from the Lingang Special Area Administrative Committee, Fudan University, Shanghai Jiao Tong University, Tongji University, East China Normal University, Shanghai University, Lingang Laboratory, the Shanghai Lingang Science and Technology Innovation and Development Foundation, and the World Laureates Foundation, as well as more than 20 media representatives.

View original content:https://www.prnewswire.com/news-releases/leading-a-paradigm-shift-exploring-the-next-decade-together–2026-world-laureates-forum-to-take-place-in-shanghai-from-october-30-to-november-1-302920432.html

SOURCE Yicai Global

Continue Reading

Technology

CHIME and ScaleHealth Announce Joint Venture to Expand Healthcare’s Innovation Ecosystem

Published

on

By

ScaleHealth, powered by CHIME, creates new pathways connecting healthcare leaders, innovators, technology partners, and investors to accelerate the future of digital health.

ANN ARBOR, Mich., Oct. 27, 2026 /PRNewswire/ — The College of Healthcare Information Management Executives (CHIME) today announced a strategic joint venture with ScaleHealth, Inc. to create ScaleHealth, powered by CHIME, LLC, a new innovation ecosystem designed to connect healthcare’s most pressing challenges with the innovators, leaders, organizations, and partners capable of solving them. By combining CHIME’s trusted digital health community with ScaleHealth’s expansive innovation ecosystem, the venture creates a unique environment where healthcare organizations, entrepreneurs, established technology companies, and investors can discover, connect, validate, and advance the ideas shaping the future of healthcare.

For 35 years, CHIME has evolved alongside the digital health leaders it serves. What began as a community centered on healthcare CIOs has grown into a global network of digital health leaders supported through education, events, research, policy initiatives, media platforms, executive collaboration, and professional communities. The creation of ScaleHealth, powered by CHIME represents the next chapter in that evolution, expanding CHIME’s ecosystem to include the innovators, entrepreneurs, and emerging technology companies helping define what comes next in healthcare.

As healthcare organizations face increasing pressure to improve outcomes, strengthen operations, address workforce challenges, improve cybersecurity, and realize the promise of emerging technologies including artificial intelligence, the need for stronger connections across the innovation ecosystem has never been greater. ScaleHealth, powered by CHIME was created to help build those connections.

“CHIME has spent 35 years bringing together the leaders responsible for solving healthcare’s most important technology and transformation challenges,” said Russ Branzell, President and CEO of CHIME. “As the pace of innovation continues to accelerate, we have an opportunity to expand that trusted community even further. ScaleHealth, powered by CHIME, extends our ecosystem to include entrepreneurs, innovators, investors, and emerging technology companies so that healthcare leaders can engage earlier, collaborate more effectively, and help shape the innovations that will define the future of healthcare.”

The opportunity emerged through CHIME’s growing innovation programming, particularly its Innovation Summit series, where healthcare leaders and technology companies increasingly expressed a desire to engage more directly with innovators and entrepreneurial organizations. At the same time, startups and growth-stage companies were seeking trusted pathways into healthcare and stronger connections to leaders who understand the industry’s real-world operational challenges.

“Healthcare has no shortage of innovation. The challenge is creating trusted pathways that connect innovators with the healthcare leaders who understand the industry’s most urgent problems,” said Taylor McPartland, CEO of ScaleHealth and leader of the new venture. “By combining ScaleHealth’s innovation ecosystem with CHIME’s trusted community of digital health leaders, we’re creating an environment where meaningful connections can lead to validation, partnership, and real-world impact. This is about bringing together everyone who has a role to play in the future of healthcare innovation and helping them move great ideas forward.”

Unlike traditional accelerators, startup showcases, or innovation marketplaces, ScaleHealth, powered by CHIME is designed as a trusted innovation ecosystem. Healthcare organizations bring forward meaningful challenges. Innovators and startups contribute cutting-edge ideas and technologies. Established technology organizations bring expertise, infrastructure, and scale. Investors provide capital and growth pathways. Together, these stakeholders create an environment where innovation can move from discovery and connection to validation, partnership, and measurable impact.

“Throughout its history, CHIME has grown by bringing the right people together around the challenges that matter most,” said Tressa Springmann, Senior Vice President and Chief Information and Digital Officer at LifeBridge Health and Chair of the CHIME Foundation Board of Directors. “Today, innovation is essential to every aspect of healthcare transformation. ScaleHealth, powered by CHIME extends that trusted community into a broader innovation ecosystem, creating new opportunities for healthcare leaders, entrepreneurs, technology partners, and investors to collaborate, learn from one another, and accelerate meaningful progress across healthcare.”

The venture reflects CHIME’s belief that the next era of digital health will be co-created by healthcare leaders, technology partners, entrepreneurs, investors, and innovators working together to solve the challenges that matter most. By creating a trusted environment for discovery, collaboration, validation, and advancement, ScaleHealth, powered by CHIME aims to become the connective layer between healthcare’s needs and the innovation being built to address them.

Read the full release here.

About CHIME
The College of Healthcare Information Management Executives (CHIME) is the leading professional organization for digital health executives and leaders. CHIME provides a trusted, collaborative environment where members and partners connect, share best practices, advance professional development, and advocate for the effective use of information and technology to improve health and care in the communities they serve. For more information, please visit chimecentral.org.

For media inquiries, please contact:

Contact

Calli Dretke
Executive Vice President & Chief Digital and Marketing Officer
CHIME                                                                                                           
734.412.6255
cdretke@dhinsights.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/chime-and-scalehealth-announce-joint-venture-to-expand-healthcares-innovation-ecosystem-302921260.html

SOURCE College of Healthcare Information Management Executives (CHIME)

Continue Reading

Technology

In HelloNation, Prenatal Imaging Expert Erika Lambright Explains Ultrasound Differences Between 2D, 3D, And 4D Imaging

Published

on

By

The article outlines how each type of pregnancy ultrasound supports fetal development and family understanding.

DENISON, Texas, Oct. 27, 2026 /PRNewswire/ — What is the difference between 2D, 3D, and 4D ultrasound imaging during pregnancy? HelloNation has published an article that clearly explains the differences between ultrasound and other prenatal imaging modalities and how each supports fetal development.

The HelloNation article explains that a 2d ultrasound is the most common form of prenatal imaging used during routine pregnancy ultrasound appointments. It produces flat, black-and-white images that allow medical providers to assess fetal development, monitor growth, and evaluate vital structures. The article notes that 2D ultrasound plays a central role in identifying potential concerns early and remains the foundation of prenatal diagnostic imaging.

According to the article, a 3d ultrasound builds on the same technology but creates a more detailed still image with depth. This form of prenatal imaging allows families to see clearer views of the baby’s face, hands, and feet. While 3d ultrasound can support certain medical evaluations, the article describes its primary value as helping parents better visualize fetal development in a more lifelike way.

The article further describes how a 4D ultrasound adds motion to the 3d ultrasound image. This allows families to view real-time video of the baby moving, stretching, or making facial expressions. The article explains that this type of pregnancy ultrasound creates a more engaging experience and helps strengthen the emotional connection, while still using the same safe, noninvasive prenatal imaging technology.

The HelloNation article emphasizes that understanding ultrasound differences helps families set clear expectations before imaging sessions. Each type of pregnancy ultrasound serves a distinct purpose. 2D ultrasound focuses on medical accuracy and fetal development monitoring, while 3D and 4D ultrasound provide enhanced visualization and connection. The article highlights that medical professionals typically rely on 2D ultrasound for diagnostic purposes, while 3D and 4D ultrasound are often optional.

The article also notes that several factors can affect the quality of prenatal imaging results. Baby position, gestational age, and fluid levels all play a role in how clearly images appear, especially during 3D and 4D ultrasound sessions. The article explains that providers often guide families on the best timing for ultrasound visits during pregnancy to improve image clarity and achieve better results.

Prenatal Imaging Experts emphasize through the article that learning about ultrasound differences can reduce uncertainty and help families feel more prepared. By understanding how each type of prenatal imaging contributes to monitoring fetal development, expectant parents can approach each pregnancy ultrasound appointment with clearer expectations.

The article concludes that while 2D ultrasound remains essential for medical care, the added perspectives of 3D and 4D ultrasound offer families a broader, more personal understanding of fetal development. Together, these forms of prenatal imaging provide both clinical insight and meaningful connection throughout pregnancy.

What Is the Difference Between 2D, 3D, and 4D Ultrasounds Explained Simply features insights from Erika Lambright, Prenatal Imaging Experts of Denison, Texas, in HelloNation.

About HelloNation
HelloNation is America’s Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused digital publications and innovative “edvertising” approach, HelloNation delivers expert-driven, good-news content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities. HelloNation maintains partnerships with the U.S. Conference of Mayors and the United States First Responders Association.

View original content to download multimedia:https://www.prnewswire.com/news-releases/in-hellonation-prenatal-imaging-expert-erika-lambright-explains-ultrasound-differences-between-2d-3d-and-4d-imaging-302792440.html

SOURCE HelloNation

Continue Reading

Technology

Grünenthal presents Phase III results for Qutenza® in post-surgical neuropathic pain at IASP 2026 World Congress on Pain

Published

on

By

Late-breaking data from the Phase III RISE trial further strengthen the well-established efficacy and safety profile of Qutenza®. Post-surgical neuropathic pain is a debilitating complication of surgery affecting millions of patients every year.1 

AACHEN, Germany, Oct. 27, 2026 /PRNewswire/ — Grünenthal, a global leader in pain management and research, today announced new data from the Phase III RISE trial (NCT04967664), evaluating Qutenza® versus control in people with post-surgical neuropathic pain. These data were shared today as late-breaking poster presentations at the 2026 International Association for the Study of Pain (IASP) World Congress on Pain in Bangkok, Thailand.

The trial (n=409) showed that Qutenza® achieved a statistically significantly greater reduction in average pain intensity (API) than the control treatment over weeks 2-12, meeting one of its pre-specified primary endpoints. When evaluating API at week 12 specifically, at the point when patients would typically return for retreatment, the numerical difference favoured Qutenza® but did not reach statistical significance. In the extension phase of the trial, in which up to 4 retreatments were allowed, Qutenza® achieved a statistically significantly greater reduction in API than the control treatment over weeks 2-42. Safety findings were consistent with previous Qutenza® trials and no new safety signals were observed. These data support the well-established efficacy and safety profile of Qutenza®.2,3

“Post-surgical neuropathic pain can be difficult to manage with current treatment options, and there is an urgent need for patient-centred, effective solutions. The RISE trial provides encouraging evidence that Qutenza® can deliver clinically meaningful and sustained pain reduction for up to 42 weeks, having shown a greater reduction in average pain intensity than the control,” said Prof. Patrice Forget, MD, PhD, FFPMRCA, Clinical Chair (full professor) in Anaesthesia, University of Aberdeen, and Honorary Consultant, NHS Grampian, Aberdeen, UK. “As IASP shines a global spotlight on neuropathic pain at this year’s congress, findings such as these are important to help improve outcomes for patients and reduce the burden of pain on families and healthcare systems.”

“Post-surgical neuropathic pain has been relatively understudied and continues to go under-recognised in clinical practice,” said Uli Brödl, Chief Scientific Officer, Grünenthal. “These results build on the robust body of evidence for Qutenza® and reinforce its potential to provide meaningful, long-lasting pain relief for people living with pain.”

Post-surgical neuropathic pain is a poorly recognised potential complication of surgery that can result in devastating outcomes. It affects millions of patients every year, with pain lasting for months or years post-procedure.1 It can also have a significant mental health impact, with patients reporting feeling extremely depressed or anxious, and having problems with daily activities.4

Qutenza® is already approved in Europe for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain.5 It is also approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults.6

About the RISE trial2,3
The RISE (AV-001) trial is a Phase III multi-centre, randomised, double-blind, parallel-group trial to confirm the efficacy and safety of Qutenza 179mg cutaneous patch versus a low-dose capsaicin control patch in people with moderate to severe post-surgical neuropathic pain.

It included eligible adults with a 24-hour average pain intensity (API) score of 4 or more, a pain duration of 6 to 60 months after index surgery and a DN4 (Douleur Neuropathique 4) Interview score of 3 or more.

Participants were randomly assigned to receive treatment with either a 60-minute Qutenza patch (8%) or a low-dose capsaicin control patch (0.04%).

The trial had two primary endpoints:

Change in 24-hour API from baseline to the average score of the entire period between Week 2 and Week 12.Change in 24-hour API from baseline to the average score at Week 12.

The primary sponsor of the trial is Averitas Pharma, Inc., Grünenthal’s U.S. subsidiary.

About post-surgical neuropathic pain
Post-surgical neuropathic pain (PSNP) is defined as chronic pain with neuropathic characteristics that develops or increases after surgery and persists beyond the normal healing process. It is thought to arise, at least in part, from nerve injury and pain sensitisation associated with surgery.7

The signs and symptoms of peri- and post-surgical pain can vary based on the person and the severity of the injury caused in surgery. Reported symptoms include pain caused by stimuli that are normally painless (allodynia), abnormally increased sensitivity to pain (hyperalgesia), tingling, numbness, phantom pain and scar pain.8,9,10 

About Qutenza®
In Europe, Qutenza® (capsaicin) is indicated for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain.5

Qutenza® (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Important US safety information is available at www.qutenza.com.6

Qutenza® is a topical TRPV1 agonist, designed to provide neuropathic pain relief for up to three months through defunctionalisation of nociceptors and nerve fibre regeneration.

About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2025, Grünenthal employed around 4,100 people and achieved revenues of €1.8 billion.

More information: www.grunenthal.com

Follow us on LinkedIn & Instagram

For further information, please contact:

Matt Crabb, Head of Global Communications (Interim) at Grünenthal

matt.crabb@grunenthal.com 

References

1 Gregory P & Settles K. Pract Pain Manag. 2013;13(9):1–6.
2 Wallace M et al. Efficacy of high-concentration capsaicin patch in post-surgical neuropathic pain (RISE). Presented at the International Association for the Study of Pain World Congress 2026.
3 Wallace M et al. Safety and tolerability of high-concentration capsaicin patch in post-surgical neuropathic pain (RISE). Presented at the International Association for the Study of Pain World Congress 2026.
4 Santos MP, Lemos F, Gomes J, Romao JM, Veiga D. Br J Pain 2024;18(1):42–56.
5 European Medicines Agency. Qutenza 179 mg cutaneous patch SmPC. Available at: https://www.medicines.org.uk/emc/product/573/smpc
6 US Food and Drug Administration. Qutenza® Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022395s019lbl.pdf
7 Correl D. F1000Res. 2017;6:1054.
8 Werner MU & Kongsgaard UE. Br J Anaesth. 2014;113(1):1–4.
9 Macrae WA. Br J Anaesth. 2008;101:77–86.
10 Searle RD & Simpson KH. Contin Educ Anaesth Crit Care Pain. 2010;10:12–14.

View original content:https://www.prnewswire.com/news-releases/grunenthal-presents-phase-iii-results-for-qutenza-in-post-surgical-neuropathic-pain-at-iasp-2026-world-congress-on-pain-302921015.html

SOURCE Grünenthal Group

Continue Reading

Trending